Coloplast A/S (OTCMKTS:CLPBY) Downgraded by Barclays to “Hold”

Barclays lowered shares of Coloplast A/S (OTCMKTS:CLPBY) from a strong-buy rating to a hold rating in a research note issued to investors on Wednesday,Zacks.com reports.

CLPBY has been the subject of a number of other research reports. Royal Bank of Canada raised Coloplast A/S from a “hold” rating to a “moderate buy” rating in a report on Monday, March 3rd. Sanford C. Bernstein raised Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 28th. Three equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Coloplast A/S Stock Performance

Coloplast A/S stock opened at $9.66 on Wednesday. Coloplast A/S has a 12 month low of $9.57 and a 12 month high of $14.14. The stock’s 50 day simple moving average is $10.51 and its two-hundred day simple moving average is $11.30. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.66 and a current ratio of 1.02.

Coloplast A/S (OTCMKTS:CLPBY) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Coloplast A/S had a return on equity of 28.60% and a net margin of 17.81%. The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $7.02 billion. On average, equities analysts expect that Coloplast A/S will post 0.31 earnings per share for the current year.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.